Biosimilars High Impact Factor Journals
A biosimilar is a biological product which is being produced to be identical to a biologic already licensed by the FDA, known as the reference drug. To think of a biosimilar as a "natural" version of the reference drug might be enticing. There are still several important variations between biosimilars and generic variants of traditional drugs. A generic medication is functionally similar to an exact clone of its brand-name equivalent. This has the same active component, dosage type, protection profile, power, route of administration, efficiency characteristics and planned usage. The brand-name drug and generic drug are thus considered bioequivalent. A biosimilar does not represent an exact duplicate of another biologic. All biological products have a degree of natural variability; a precise copy of a product that comes from living
cells cannot be generated. All the biologics — including reference products — show any difference from batch to batch. A biosimilar may have a different structure than the reference product but in molecular and biological terms, the active substances are essentially the same. That means there are no clinically meaningful differences in safety or effectiveness between the biosimilar and the reference product. Only minor differences are admissible in clinically inactive components.
High Impact List of Articles
Relevant Topics in Clinical